In the Spotlight...
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity
CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors
Previous Digests
Activated DCs go beyond priming to sustain tumoral T cell responses
August 12, 2026
A subset of cDCs within tumors expresses T cell-stimulating and immune-regulatory molecules. The exact role of these activated DCs (actDCs) in antitumor immunity remains largely unknown, and given their scarcity, they are a challenge to study. Koufaki et al...
Helpers don’t clock out: CD4s essential for both priming and effector phases of ICB
August 5, 2026
While CD4+ T cells are crucial for CD8+ T cell priming in ICB-induced antitumor responses, their helper role at the effector phase remains largely unknown. Ameh et al. used murine MHC-II- sarcoma models to study CD4+ T cell help...
cDC1s serve as architects for the formation and maintenance of tumoral TLSs
July 29, 2026
The presence of tertiary lymphoid structures (TLSs) in tumors is associated with improved outcomes and response to immune checkpoint blockade (ICB). Although the cell populations within these TLSs are well established, the precise contributions of DCs to TLS formation...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
